Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study
The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 2078-2086
DOI: 10.1210/clinem/dgad039 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.01.2023. Verfasst von Ling Hou und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism, Pituitary. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Key Research and Development Program of China is funded by Ministry of Science and Technology of the People's Republic of China, The Special Science and Technology Major Project of Hubei Province is funded by Hubei Provincial Science and Technology Department.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
The evidence of long-term polyethylene glycol recombinant human GH (PEG-rhGH) in pediatric GH deficiency (GHD) is limited.
Objective
This study aimed to examine the effectiveness and safety of long-term PEG-rhGH in children with GHD in the real world, as well as to examine the effects of dose on patient outcomes.
Design
A prospective, observational, posttrial study (NCT03290235). Setting, participants and intervention Children with GHD were enrolled from 81 centers in China in 4 individual clinical trials and received weekly 0.2 mg/kg/wk (high-dose) or 0.1 to <0.2 mg/kg/wk (low-dose) PEG-rhGH for 30 months. Main outcomes measures Height SD score (Ht SDS) at 12, 24, and 36 months.
Results
A total of 1170 children were enrolled in this posttrial study, with 642 patients in the high-dose subgroup and 528 in the low-dose subgroup. The Ht SDS improved significantly after treatment in the total population (P < 0.0001), with a mean change of 0.53 ± 0.30, 0.89 ± 0.48, 1.35 ± 0.63, 1.63 ± 0.75 at 6 months, 12 months, 24 months, and 36 months, respectively. In addition, the changes in Ht SDS from baseline were significantly improved in the high-dose subgroup compared with the low-dose subgroup at 6, 12, 24, and 36 months after treatment (all P < 0.05). A total of 12 (1.03%) patients developed serious adverse events. There was no serious adverse event related to the treatment, and no AEs leading to treatment discontinuation or death occurred.
Conclusions
PEG-rhGH showed long-term effectiveness and safety in treating children with GHD. Both dose subgroups showed promising outcomes, whereas PEG-rhGH 0.2 mg/kg/wk might show additional benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Endocrinology, National Clinical Research Center for Child Health, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.
- Department of Endocrine and Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
- Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children's Hospital of Fudan University, Shanghai 201102, China.
- Department of Endocrinology and Metabolism, Genetics, Henan Children's Hospital (Children's Hospital Affiliated to Zhengzhou University), Zhengzhou 450018, China.
- Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
ORCID-Profile: Ke Huang
Förderung
- The National Key Research and Development Program of China is funded by Ministry of Science and Technology of the People's Republic of China
- The Special Science and Technology Major Project of Hubei Province is funded by Hubei Provincial Science and Technology Department
Zitieren
APA
Hou, L., Huang, K., Gong, C., Luo, F., Wei, H., Liang, L., Du, H., Zhang, J., Zhong, Y., Chen, R., Chen, X., Pan, J., Jin, X., Zeng, T., Liao, W., Liu, D., Lan, D., Zhu, S., Dong, Z., …, & Ying, L. (2023). Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study. The Journal of Clinical Endocrinology & Metabolism, 108(8), 2078-2086. https://doi.org/10.1210/clinem/dgad039
Vancouver
Hou L, Huang K, Gong C, Luo F, Wei H, Liang L, et al. Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):2078-2086. doi:10.1210/clinem/dgad039
BibTeX
@article{Hou2023,
author = {Hou, Ling and Huang, Ke and Gong, Chunxiu and Luo, Feihong and Wei, Haiyan and Liang, Liyang and Du, Hongwei and Zhang, Jianping and Zhong, Yan and Chen, Ruimin and Chen, Xinran and Pan, Jiayan and Jin, Xianjiang and Zeng, Ting and Liao, Wei and Liu, Deyun and Lan, Dan and Zhu, Shunye and Dong, Zhiya and Ma, Huamei and Yang, Yu and Xiong, Feng and Lu, Ping and Cheng, Shengquan and Gu, Xuefan and Jin, Runming and Liu, Yu and Wu, Jinzhun and Xu, Xu and Chen, Linqi and Dong, Qin and Pan, Hui and Su, Zhe and Liu, Lijun and Luo, Xiaoming and Ni, Shining and Chen, Zhihong and Hu, Yuhua and Wang, Chunlin and Liu, Jing and Liu, Li and Lu, Biao and Wang, Xinli and Wang, Yunfeng and Yang, Fan and Zhang, Manyan and Cao, Lizhi and Liu, GeLi and Yao, Hui and Zhan, Yaqin and Dai, Mingjuan and Li, Guimei and Li, Li and Liu, Yanjie and Wang, Kan and Xiao, Yanfeng and Zhang, Xingxing and Dong, Junhua and Gu, Zaiyan and Ying, Lirong},
title = {Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {8},
pages = {2078--2086},
doi = {10.1210/clinem/dgad039}
}
EUVIMED